Wall Street analysts expect that Inovio Pharmaceuticals Inc (NASDAQ:INO) will post earnings of ($0.20) per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Inovio Pharmaceuticals’ earnings, with estimates ranging from ($0.29) to ($0.07). Inovio Pharmaceuticals reported earnings per share of ($0.08) during the same quarter last year, which suggests a negative year over year growth rate of 150%. The firm is expected to report its next quarterly earnings results on Tuesday, August 6th.
According to Zacks, analysts expect that Inovio Pharmaceuticals will report full-year earnings of ($1.01) per share for the current year, with EPS estimates ranging from ($1.06) to ($0.93). For the next financial year, analysts forecast that the firm will post earnings of ($1.05) per share, with EPS estimates ranging from ($1.22) to ($0.93). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Inovio Pharmaceuticals.
Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.01). Inovio Pharmaceuticals had a negative net margin of 295.24% and a negative return on equity of 97.95%. The firm had revenue of $2.83 million for the quarter, compared to analysts’ expectations of $4.44 million.
In other Inovio Pharmaceuticals news, insider Laurent Humeau bought 20,000 shares of the firm’s stock in a transaction on Wednesday, June 5th. The shares were acquired at an average cost of $2.50 per share, for a total transaction of $50,000.00. Following the purchase, the insider now directly owns 45,833 shares of the company’s stock, valued at $114,582.50. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Jong Joseph Kim sold 2,129,553 shares of the stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $2.36, for a total value of $5,025,745.08. Following the transaction, the chief executive officer now owns 1,911,055 shares in the company, valued at $4,510,089.80. The disclosure for this sale can be found here. Insiders sold a total of 2,866,321 shares of company stock worth $7,055,433 over the last 90 days. Corporate insiders own 7.90% of the company’s stock.
Several institutional investors have recently made changes to their positions in INO. Nikko Asset Management Americas Inc. bought a new position in shares of Inovio Pharmaceuticals during the 1st quarter valued at about $12,169,000. Sumitomo Mitsui Trust Holdings Inc. bought a new position in shares of Inovio Pharmaceuticals during the 1st quarter valued at about $11,896,000. ARK Investment Management LLC increased its position in shares of Inovio Pharmaceuticals by 55.4% during the 1st quarter. ARK Investment Management LLC now owns 2,929,597 shares of the biopharmaceutical company’s stock valued at $10,927,000 after purchasing an additional 1,043,956 shares during the last quarter. D. E. Shaw & Co. Inc. increased its position in shares of Inovio Pharmaceuticals by 125.2% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,073,086 shares of the biopharmaceutical company’s stock valued at $4,292,000 after purchasing an additional 596,684 shares during the last quarter. Finally, Wasatch Advisors Inc. grew its position in Inovio Pharmaceuticals by 9.6% during the 1st quarter. Wasatch Advisors Inc. now owns 5,848,410 shares of the biopharmaceutical company’s stock worth $21,815,000 after acquiring an additional 510,480 shares during the last quarter. Hedge funds and other institutional investors own 47.24% of the company’s stock.
Shares of NASDAQ INO opened at $2.52 on Friday. Inovio Pharmaceuticals has a one year low of $2.15 and a one year high of $6.30. The company has a debt-to-equity ratio of 1.02, a current ratio of 4.92 and a quick ratio of 4.92. The company’s fifty day moving average price is $2.93. The stock has a market cap of $233.61 million, a PE ratio of -2.40 and a beta of 1.96.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Read More: Economic Reports
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.